MedTrace Logo

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

NCT04563975 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-03-17

No results posted yet for this study

Summary

The single arm clinical study is to evaluate the efficacy and safety of an anti-PD-1 antibody (Toripalimab) combined with chemotherapy (docetaxel or nab-Paclitaxel) in patients with advanced gastric cancer who failed first-line treatment.

Conditions

  • Gastric Cancer Stage IV

Interventions

DRUG

Toripalimab

Toripalimab，240mg，d1，Intravenous Infusion，q3w

DRUG

Docetaxel

Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w

DRUG

nab-paclitaxel

nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w

Sponsors & Collaborators

  • Tao Zhang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-02
Primary Completion
2022-12-31
Completion
2023-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04563975 on ClinicalTrials.gov